ibodutant

Ibodutant is a selective, potent, orally active small molecule antagonist of the neurokinin 2 (NK₂; tachykinin receptor NK₂; gene symbol TACR2) receptor. It was developed primarily for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Tachykinins and their receptors are implicated in gastrointestinal motility and visceral sensitivity. By blocking the NK₂ receptor on smooth muscle and enteric neurons in the gut, ibodutant was intended to reduce symptoms such as abdominal pain and abnormal stool consistency associated with IBS-D. The drug showed dose-dependent efficacy in clinical trials—particularly at a 10 mg daily dose in female patients—but development was discontinued after phase III studies due to insufficient overall response[3][5][8].

Other names

522664-63-7Ibodutant [INN]UNII-1H7RSQ28BJUNII1H7RSQ28BJUNII 1H7RSQ28BJ6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4-yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamideIBODUTANT [WHO-DD]6-Methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl(((1-(tetrahydropyran‑4‑ylmethyl)piperidin‑4‑ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide)Benzo(b)thiophene‑2‑carboxamide, 6-methyl-N-(1–((((1R)-2–oxo–1–(phenylmethyl)-2–(((1–((tetrahydro‑2H-pyran‑4-y)methy l)-4-piperidin yl)meth yl)a mino ) eth yl)a mino )carbon yl)c yclopent yl)